IDEAYA Biosciences (IDYA) Other Accumulated Expenses (2018 - 2026)

IDEAYA Biosciences has reported Other Accumulated Expenses for 9 years, with the latest figure at $1.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 95.43% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 95.43% YoY) and the FY2025 annual result came in at $1.1 million, down 94.68% from the prior year.
• Other Accumulated Expenses rose to $1.2 million in Q1 2026 per IDYA's latest filing, from $1.1 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $32.9 million in Q3 2025 and troughed at $92000.0 in Q4 2022.
• A 5-year average of $9.2 million and a median of $5.9 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses tumbled 98.83% in 2022, then soared 11504.35% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $92000.0 in 2022, then jumped by 11504.35% to $10.7 million in 2023, then jumped by 86.92% to $20.0 million in 2024, then plunged by 94.68% to $1.1 million in 2025, then increased by 11.86% to $1.2 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.2 million, $1.1 million, and $32.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.